#1870 Bevacizumab-associated renal events: incidence, risk factors, and relationship with mortality
Abstract
Bevacizumab, an anti-VEGF antibody, is a cornerstone in the treatment of ovarian cancer. VEGF inhibition is associated with kidney damage, but its impact on mortality remains unclear. The aim of this study is to determine the incidence of renal event (RE), associated risk factors for RE, and the association of RE with mortality in a series of patients with ovarian cancer treated with bevacizumab.
A single-center retrospective study including patients with ovarian cancer treated with bevacizumab between January 2011 and December 2023. Follow-up until April 2024. RE definition: New-onset or worsening hypertension (HTN), proteinuria, acute kidney injury (AKI), and/or a combination of these.
147 patients, mean age 63.0 ± 11.9 years; 22.5% FIGO stage IV (metastatic disease). At baseline, 6.1% had an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m², 8.8% had proteinuria, and 34.7% had HTN. Mean follow-up: 62.9 ± 123.5 months. 34.7% presented RE (6.8% AKI, 7.5% proteinuria, 30.6% HTN, Fig. 1) at 4.9 ± 5.1 months after initiating bevacizumab. In 15.7% of cases, RE led to bevacizumab discontinuation. Two renal biopsies were performed, both showing thrombotic microangiopathy. Patients who presented RE did not show statistically significant differences in terms of age, FIGO stage, treatment line, or baseline chronic kidney disease (CKD)/type 2 diabetes mellitus (T2DM) compared to those without RE. However, baseline HTN was significantly more common in patients who…
Read the paper
Related studies
- Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale
- Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
- Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials
- Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
- Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.